阿达木单抗治疗斑块型银屑病疗效及代谢综合征对疗效的影响

目的：明确阿达木单抗治疗斑块型银屑病患者的疗效。方法：收集2020年9月至2021年3月经阿达木单抗治疗的斑块型银屑病患者，分析经阿达木单抗治疗0、4、8、12周的PASI评分变化及相关性。结果：共收集20例患者，其中1例中断治疗，19例患者中伴和不伴代谢综合征患者分别为11例和8例。经阿达木单抗治疗12周后，19例患者PASI评分自基线时的9.7（2.0,15.6）下降到3.3（0.4,4.2）。伴代谢综合征患者中达到PASI 75/PASI 90患者分别为45%和0%，不伴代谢综合征患者分别为50%和50%。代谢综合征与疗效存在负相关性（r=-0.679，P＜0.01）。结论：阿达木单抗治疗斑块型银屑病有效，代谢综合征影响疗效。

Efficacy of adalimumab in the treatment of plaque psoriasis with or without metabolic syndrome

Objective: To investigate the efficacy of adalimumab in the treatment of plaque psoriasis with or without metabolic syndrome. Methods: The data of patients with plaque psoriasis (with or without metabolic syndrome) from September 2020 to March 2021 were collected. PASI change at 0, 4, 8, 12 weeks and Spearman's correlation of the patients treated with adalimumab were analyzed. Results: A total of 20 patients with psoriasis were treated with adalimumab, of which 1 case was interrupted. Of 19 patients who completed treated, 11 were complicated with  metabolic syndrome. The PASI of 19 patients from 9.7 (2.0, 15.6) to 3.3 (0.4, 4.2). The rate of the patients with metabolic syndrome recovered to PASI 75/PASI 90 were 45% and 0%, that of the patients with no metabolic syndrome were 50% and 50%. There was a negative correlation between efficacy of adamizumab and metabolic syndrome in patients with plaque psoriasis (r=0.679, P<0.01). Conclusion: Adalimumab is effective in the treatment of plaque psoriasis, and metabolic syndrome reduces the effect of adalimumab.